酒火炙水蛭的生物活性考察

目的:评价酒火炙水蛭的生物活性及安全性。方法:采用SNK法统计生水蛭、酒炙水蛭、酒火炙水蛭3组的抗凝血酶活性,并进行小鼠最大给药量实验:给予小鼠156mg酒火炙水蛭1d的最大给药量(相当于《中国药典》规定成人每日最大服用量的130倍)。结果:传统酒炙水蛭组与生水蛭组、酒火炙水蛭组比较,均有显著性差异P<0.05;酒火炙水蛭组与生水蛭组比较无显著性差异(P>0.05)。安全性实验小鼠未见异常,无死亡。结论:酒火炙水蛭具有较好抗凝活性,且用药安全。     

Physical activity,skeletal muscle β-adrenoceptor changes and oxidative metabolism in experimental chronic heart failure†

Summary— In chronic heart failure (CHF), changes in sympathetic nervous activity and skeletal muscle metabolism contribute to a limitation in the capacity for exercise. The aim of this study was to investigate the potential relationships between physical deconditioning, skeletal muscle β-adrenoceptor (β-AR) characteristics and muscle metabolic changes in rats with coronary ligation-induced experimental CHF. Muscle β-AR and norepinephrine levels were assessed in rats with CHF that had been treated with propranolol at 28 mg/kg/day and compared with rats with CHF that had not been treated and those that had undergone sham operations. The soleus muscle was investigated because of its predominantly oxidative fibre-type composition. Measurements of spontaneous locomotion activity were carried out using telemetry. After 85 days, muscle energetic phosphate levels were assessed using ³¹P-magnetic resonance spectroscopy. The phosphocreatine resynthesis rate was decreased in the untreated CHF rats (15 ± 3 vs 33 ± 5 mmol L^?1 min^?1 in the sham-operated rats, p < 0.05), but this had been partially reversed in the rats given propranolol (22 ± 3 mmol L^?1 min^?1, non-significant (NS) when compared with the sham-operated rats). Spontaneous activity did not differ among the three groups of animals. Soleus β-adrenoceptor density was decreased in rats with CHF (8.8 ± 3.0 fM/mg of protein vs 22.0 ± 7.0 fM/mg of protein in the sham-operated rats, p < 0.05) and normalized in the propranolol-treated rats (31.9 ± 7.0 fM/mg of protein, NS vs the sham-operated rats; p < 0.05 vs the untreated rats with CHF). Unchanged spontaneous activity in the rats with CHF suggests that physical deconditioning could not account for the muscle metabolic changes. Changes in skeletal muscle energy metabolism were accompanied by changes in β-AR density, occurring in typically oxidative β-AR-rich muscles, reversible after β-blocker therapy and therefore suggestive of β-AR downregulation.     

新疆地区107例低体质量婴儿先天性心脏病的外科治疗

目的:探讨新疆地区体质量5 kg以下少数民族婴儿,先天性心脏病(先心病)的外科治疗方法及围术期处理。方法:2006年7月至2011年12月,本院手术治疗5 kg以下先心病患儿107例,年龄11 d至13个月,体质量2.6～5 kg。病种包括:动脉导管未闭(PDA)4例,室间隔缺损(VSD)和(或)房间隔缺损(ASD)54例,其中部分伴动脉导管未闭(PDA)和(或)肺动脉高压(PH),肺动脉瓣狭窄(PS)1例,法洛三联症3例,法洛四联症(TOF)9例,完全性心内膜垫缺损(ECD)9例,右心室双出口(DORV)9例,完全性大血管转位(TGA)8例(室间隔完整4例,室间隔缺损4例),完全性肺静脉异位引流(TAPVC)3例,主动脉弓缩窄(COA)并室间隔缺损、房间隔缺损3例,肺动脉闭锁(PA)2例,三尖瓣闭锁(TA)1例,房室连接不一致1例。本组中I期根治手术96例,减状手术11例(肺动脉环缩术6例,中心分流术4例,右心室流出道疏通术1例);体外循环下手术93例,其中深低温停循环3例。结果:本组术后早期死亡6例(5.6%),死于低心排出量综合征(低心排)1例,多脏器衰竭2例,呼吸衰竭2例,凝血功能障碍1例。术后主要并发症:低心排9例,多脏器损害5例,肾衰竭3例,肺部感染28例,心律失常3例,切口感染3例,心包积液2例,残余分流1例及乳糜胸1例。随访2个月～5年,81例无中期死亡,再手术3例。结论:严格评估低体质量先心病患儿手术适应证和时机,加强围手术期处理,是提高治疗效果的关键。     

Percutaneous transluminal angioplasty of the subclavian arteries.

PURPOSE: To review the feasibility, risks, and long-term results of subclavian artery angioplasty with and without Palmaz stent placement. METHODS: Over a 9-year period, 113 patients (67 males; mean age 63 +/- 13 years) underwent percutaneous balloon angioplasty of subclavian occlusive lesions for a variety of indications: vertebrobasilar insufficiency (n = 70), upper limb ischemia (n = 50), coronary steal syndrome (n = 6), or anticipated coronary artery bypass grafting using the internal mammary artery in 12 asymptomatic patients. There were 94 (83%) stenoses and 19 (17%) occlusions with a mean percent stenosis of 80.1% +/- 7.4% (range 70 to 100). Mean lesion length was 24 +/- 8 mm (range 10 to 50). Beginning in 1989, stents were implanted for suboptimal dilation; in 1995, stenting became routine. RESULTS: Overall, 103 (91%) of 113 lesions were successfully treated; 10 (53%) occlusions could not be recanalized. Fifty-one stents were implanted in 46 patients. There were 3 (2.6%) procedural complications: a transient ischemic attack, one major (fatal) stroke, and an arterial thrombosis 24 hours after the procedure (treated medically) (0.9% major stroke and death rate). During a mean 4.3-year follow-up (range to 10), 16 (15.5%) restenoses were treated with angioplasty (n = 4), stenting (n = 7), or surgery (n = 5). Primary and secondary patencies for all treated lesions (n = 113) at 8 years were 75% and 81%, respectively; in patients without initial stent placement, the rates were 69% and 76%, while in those with stents, the rates rose slightly to 87% and 94% at 2.5 years (NS). Patency rates for all 103 recanalized lesions were 83% and 90% at 8 years (81% and 90% without stent and 87% and 94% with stent at 2.5 years, respectively [NS]). CONCLUSIONS: Balloon angioplasty with or without stenting is safe and effective for treating subclavian artery occlusive diseases with good long-term patency. Recanalization of occlusions is more difficult to achieve. Stents (implanted only for suboptimal dilation) do not seem to improve long-term patency.     

Stents in the treatment of renal artery stenosis: long-term follow-up.

PURPOSE: To evaluate the role of percutaneous stenting in the treatment of renal arterial lesions after failure of balloon angioplasty. METHODS: Two hundred ten patients (139 males; mean age 67.7 +/- 9.9 years, range 27 to 87) had 259 balloon-expandable stents (165 Palmaz and 94 Renal Bridge stents) implanted in 244 renal artery stenoses (171 ostial and 73 nonostial lesions). The patients were suffering from intractable hypertension (n = 210) and/or renal dysfunction (n = 48). The majority of the lesions (n = 234) were atheromatous in origin. Stents were implanted for suboptimal balloon dilation (n = 182, 75%), restenotic lesions (n = 27, 11%), or dissection (n = 9, 4%); 26 (11%) ostial lesions were stented primarily. Mean lesion length was 11.9 +/- 4.4 mm (range 5 to 30) and mean percent stenosis was 81.9% +/- 8.25% (range 70 to 100). RESULTS: Immediate technical success was 99% (241 of 244). Three (1.2%) major complications included one intraprocedural stent thrombosis, one arterial perforation manifesting as a perirenal hematoma 24 hours after the procedure, and one renal arterial rupture. Follow-up over a mean 25.4 +/- 22.8 months (range 1 to 96) in 185 eligible patients (209 arteries) found 24 cases of restenosis (11.4%). Primary and secondary patencies for all lesions at 60 months were 79% and 98%, respectively, with no significant differences between ostial and nonostial lesions or stent types. Hypertension was reversed in 35 (19%), improved in 112 (61%), and remained unchanged in 37 (20%). Renal function was improved in 29% (14 of 48), unchanged in 67% (32 of 48), and worse in 4% (2 of 48). CONCLUSIONS: Renal artery stenting is safe, effective, and may be an alternative to surgery, particularly in ostial lesions. Our experience shows reduction in the restenosis rate compared to conventional angioplasty. All ostial stenoses should be stented.     

超声心动图监护下心导管介入与经胸小切口手术治疗小儿房间隔缺损的比较

目的:评估超声心动图监护下心导管介入与经胸小切口手术治疗小儿房间隔缺损(ASD)的有效性、安全性及适用范围。方法:回顾性分析经超声心动图监护下接受心导管介入治疗与经胸小切口手术治疗的104例ASD患儿的临床资料。结果:超声心动图监护下心导管介入治疗与经胸小切口手术1次封堵成功率均为100%,并发症发生率均极低。结论:在小儿ASD的治疗中,心导管介入与经胸小切口手术各有优劣,应结合临床实际谨慎选择治疗方案;超声心动图能在术前、术中与术后为临床提供有价值的信息,其充分并正确的使用值得临床医师重视。     

Multiple Nodule Removal by Disc Excision and Segmental Resection in Multifocal Colorectal Endometriosis

Study Objective

To report postoperative outcomes after dual digestive resection for deep endometriosis infiltrating the rectum and the colon.

Endovascular treatment of the subclavian artery: stent implantation with or without predilatation.

The endovascular treatment of subclavian artery (SA) lesions is less invasive than open surgical repair, with a low rate of complications. We report our experience in 89 subclavian obstructive lesions (n = 86) treated with stenting: 76 (85.3%) stenoses and 13 (14.6%) total occlusions. The left side was most frequently involved (83.1%), localized at the prevertebral segment in 91%. Technical success was obtained in 83 (93.3%) cases, 100% in stenotic lesions and 53.8% in total occlusions. There were nine global complications (10.1%): five (5.6%) at site of puncture, two distal embolization (2.2%), and two (2.3%) major events. The long-term follow-up was 3.51 +/- 1.98 years, during which time 13 (16.8%) restenoses and 2 (2.6%) reocclusions were noted. Subgroup analysis of patients with stenting after predilatation versus direct stenting technique showed in-hospital complications only in the first group, with a restenosis rate of 28.5% vs. 4.7%, respectively (P = 0.003). We consider stenting for SA obstructive lesions the first therapeutic option.     

Carotid stenting with cerebral protection: first clinical experience using the PercuSurge GuardWire system.

PURPOSE: To study the feasibility and safety of carotid angioplasty and stenting using a new cerebral protection device that temporarily occludes the distal internal carotid artery (ICA). METHODS: Forty-eight high-risk patients (39 men, mean age 69.1 +/- 8 years, range 54 to 86) with 53 ICA stenoses underwent percutaneous angioplasty and stenting via the femoral approach under cerebral protection afforded by a 0.014-inch GuardWire balloon occlusion device. Mean stenosis was 82.1% +/- 9.65% (range 70 to 96) and mean lesion length was 16.0 +/- 7.5 mm (range 6 to 50). Thirty-three (62%) lesions were calcified, and 38 (72%) were ulcerated. Thirty-two (60%) of the lesions were asymptomatic. With the occlusion balloon inflated in the distal ICA, the lesion was dilated and stented. The area was cleaned by aspiration and flushed via an aspiration catheter advanced over the wire. Blood samples were collected from the external carotid artery (ECA) and analyzed to measure the size and number of particles collected. Computed tomography and neurological examinations were performed the day after the procedure. RESULTS: Immediate technical success was achieved in all patients with the implantation of 38 Palmaz stents, 8 Expander stents, and 11 Wallstents. Carotid occlusion was well tolerated in all patients but 1 who had multiple, severe carotid lesions and poor collateralization. Mean cerebral flow occlusion time was 346 +/- 153 seconds during predilation and 303 +/- 143 seconds during stent placement. Total mean flow occlusion time was 542 +/- 243 seconds. One immediate neurological complication (transient amaurosis) occurred in a patient who had an anastomosis between the external carotid (EC) and ICA territories. Debris was removed in all patients with a mean 0.8-mm diameter catheter. CONCLUSION: Cerebral protection with the GuardWire device is easy, safe, and effective in protecting the brain from cerebral embolism. Larger studies are warranted.